For the year ending 2025-12-31, ATRA had -$16,694K decrease in cash & cash equivalents over the period. -$50,940K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | 32,688 |
| Stock-based compensation expense | 9,752 |
| Non-cash operating lease expense | 4,996 |
| Depreciation and amortization expense | 2,116 |
| Accretion of liability related to sale of future revenues | 3,578 |
| Amortization (accretion) of investment premiums (discounts) | -259 |
| Loss on impairment of lease right-of-use asset | 4,130 |
| Gain on derecognition of lease liabilities upon contract assignment | 3,818 |
| Other non-cash items, net | 94 |
| Accounts receivable | -229 |
| Inventories | -10,655 |
| Other current assets | -6,170 |
| Other assets | -15 |
| Accounts payable | -4,240 |
| Accrued compensation | -5,318 |
| Accrued research and development expenses | -7,902 |
| Other current liabilities | -4,516 |
| Deferred revenue | -94,376 |
| Operating lease liabilities | -5,453 |
| Other long-term liabilities | 1 |
| Net cash used in operating activities | -50,940 |
| Purchases of short-term investments | 7,885 |
| Proceeds from maturities and sales of short-term investments | 25,085 |
| Purchases of property and equipment | 0 |
| Proceeds from sale of property and equipment | 948 |
| Net cash provided by investing activities | 18,148 |
| Proceeds from sale of common stock and pre-funded warrants in registered direct offerings, net | 14,843 |
| Proceeds from issuance of common stock through atm facilities, net | 1,471 |
| Proceeds from employee stock awards | 35 |
| Principal payments on finance lease obligations | 250 |
| Other financing activities, net | -1 |
| Net cash provided by financing activities | 16,098 |
| Decrease in cash, cash equivalents and restricted cash | -16,694 |
| Cash, cash equivalents and restricted cash at beginning of period | 25,176 |
| Cash, cash equivalents and restricted cash at end of period | 8,482 |
Atara Biotherapeutics, Inc. (ATRA)
Atara Biotherapeutics, Inc. (ATRA)